Agin-Liebes, GI, Malone, T, Yalch, MM, et al. (2020) Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology 34(2): 155–166.
Google Scholar | SAGE Journals | ISI American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association.
Google Scholar Carhart-Harris, R, Giribaldi, B, Watts, R, et al. (2021) Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine 384(15): 1402–1411.
Google Scholar | Crossref | Medline Carhart-Harris, R, Roseman, L, Haijen, E, et al. (2018) Psychedelics and the essential importance of context. Journal of Psychopharmacology 32(7): 725–731.
Google Scholar | SAGE Journals | ISI Choi, NG, DiNitto, DM, Marti, CN, et al. (2016) Relationship between marijuana and other illicit drug use and depression/suicidal thoughts among late middle-aged and older adults. International Psychogeriatrics 28(4): 577–589.
Google Scholar | Crossref | Medline Clemens, KJ, McGregor, IS, Hunt, GE, et al. (2007) MDMA, methamphetamine and their combination: Possible lessons for party drug users from recent preclinical research. Drug and Alcohol Review 26(1): 9–15.
Google Scholar | Crossref | Medline Davis, AK, Barrett, FS, May, DG, et al. (2021) Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry 78: 481–489.
Google Scholar | Crossref | Medline Farré, M, Abanades, S, Roset, PN, et al. (2007) Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: Pharmacological effects and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics 323(3): 954.
Google Scholar | Crossref | Medline Gasser, P, Holstein, D, Michel, Y, et al. (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of Nervous and Mental Disease 202(7): 513–520.
Google Scholar | Crossref | Medline | ISI Gorska, AM, Kamińska, K, Wawrzczak-Bargieła, A, et al. (2018) Neurochemical and neurotoxic effects of MDMA (ecstasy) and caffeine after chronic combined administration in mice. Neurotoxicity Research 33(3): 532–548.
Google Scholar | Crossref | Medline Green, AR, Mechan, AO, Elliott, JM, et al. (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacological Reviews 55(3): 463–508.
Google Scholar | Crossref | Medline | ISI Griffiths, RR, Johnson, MW, Carducci, MA, et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology 30(12): 1181–1197.
Google Scholar | SAGE Journals | ISI Griffiths, RR, Richards, WA, McCann, U, et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187(3): 268–283.
Google Scholar | Crossref | Medline | ISI Grob, CS, Danforth, AL, Chopra, GS, et al. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry 68(1): 71.
Google Scholar | Crossref | Medline Havard, A, Teesson, M, Darke, S, et al. (2006) Depression among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS). Journal of Substance Abuse Treatment 30(4): 355–362.
Google Scholar | Crossref | Medline Hendricks, PS, Crawford, MS, Cropsey, KL, et al. (2018) The relationships of classic psychedelic use with criminal behavior in the United States adult population. Journal of Psychopharmacology 32(1): 37–48.
Google Scholar | SAGE Journals | ISI Hendricks, PS, Johnson, MW, Griffiths, RR (2015a) Psilocybin, psychological distress, and suicidality. Journal of Psychopharmacology 29(9): 1041–1043.
Google Scholar | SAGE Journals | ISI Hendricks, PS, Thorne, CB, Clark, CB, et al. (2015b) Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology 29(3): 280–288.
Google Scholar | SAGE Journals | ISI Jerome, L, Feduccia, AA, Wang, JB, et al. (2020). Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: A longitudinal pooled analysis of six phase 2 trials. Psychopharmacology 237(8): 2485–2497.
Google Scholar | Crossref | Medline Johnson, CS, Stansfield, CR, Hassan, VR (2020) Festival testing: A survey of suspected drugs seized from New Zealand music festivals, December 2018 to March 2019. Forensic Science International 313: 110367.
Google Scholar | Crossref | Medline Jones, G, Nock, MK (in press) MDMA/ecstasy and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of U.S adults. Journal of Psychopharmacology.
Google Scholar Kessler, RC, Merikangas, KR (2004) The National Comorbidity Survey Replication (NCS-R): Background and aims. International Journal of Methods in Psychiatric Research 13(2): 60–68.
Google Scholar | Crossref | Medline | ISI Kovács, GG, Andó, RD, Adori, C, et al. (2007) Single dose of MDMA causes extensive decrement of serotoninergic fibre density without blockage of the fast axonal transport in Dark Agouti rat brain and spinal cord. Neuropathology and Applied Neurobiology 33(2): 193–203.
Google Scholar | Crossref | Medline Lerner, M, Lyvers, M (2006) Values and beliefs of psychedelic drug users: A cross-cultural study. Journal of Psychoactive Drugs 38(2): 143–147.
Google Scholar | Crossref | Medline Liechti, ME, Gamma, A, Vollenweider, FX (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology 154(2): 161–168.
Google Scholar | Crossref | Medline Lumley, T (2020) Survey: Analysis of complex survey samples (4.0, Computer software). Available at: https://CRAN.R-project.org/package=survey
Google Scholar Lyvers, M, Meester, M (2012) Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. Journal of Psychoactive Drugs 44(5): 410–417.
Google Scholar | Crossref | Medline Mahapatra, A, Gupta, R (2017) Role of psilocybin in the treatment of depression. Therapeutic Advances in Psychopharmacology 7(1): 54–56.
Google Scholar | SAGE Journals | ISI Majumder, I, White, JM, Irvine, RJ (2011) Antidepressant-like effects of 3,4-methylenedioxymethamphetamine in an animal model of depression. Behavioural Pharmacology 22(8): 758–765.
Google Scholar | Crossref | Medline Majumder, I, White, JM, Irvine, RJ (2012) Antidepressant-like effects of ecstasy in subjects with a predisposition to depression. Addictive Behaviors 37(10): 1189–1192.
Google Scholar | Crossref | Medline Meyer, JS, Grande, M, Johnson, K, et al. (2004) Neurotoxic effects of MDMA (“ecstasy”) administration to neonatal rats. International Journal of Developmental Neuroscience: The Official Journal of the International Society for Developmental Neuroscience 22(5–6): 261–271.
Google Scholar | Crossref | Medline Mithoefer, MC, Feduccia, AA, Jerome, L, et al. (2019) MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology 236(9): 2735–2745.
Google Scholar | Crossref | Medline Mithoefer, MC, Wagner, MT, Mithoefer, AT, et al. (2011) The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. Journal of Psychopharmacology 25(4): 439–452.
Google Scholar | SAGE Journals | ISI Mithoefer, MC, Wagner, MT, Mithoefer, AT, et al. (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. Journal of Psychopharmacology 27(1): 28–39.
Google Scholar | SAGE Journals | ISI Móró, L, Simon, K, Bárd, I, et al. (2011) Voice of the psychonauts: Coping, life purpose, and spirituality in psychedelic drug users. Journal of Psychoactive Drugs 43(3): 188–198.
Google Scholar | Crossref | Medline Nour, MM, Evans, L, Carhart-Harris, R (2017) Psychedelics, personality and political perspectives. Journal of Psychoactive Drugs 49(3): 182–191.
Google Scholar | Crossref | Medline Oehen, P, Traber, R, Widmer, V, et al. (2013) A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). Journal of Psychopharmacology 27(1): 40–52.
Google Scholar | SAGE Journals | ISI Osório, F, de, L, Sanches, RF, et al. (2015) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report. Revista Brasileira de Psiquiatria 37(1): 13–20.
Google Scholar | Crossref | Medline | ISI Ot’alora, GM, Grigsby, J, Poulter, B, et al. (2018) 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. Journal of Psychopharmacology 32(12): 1295–1307.
Google Scholar | SAGE Journals Palhano-Fontes, F, Barreto, D, Onias, H, et al. (2019) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychological Medicine 49(4): 655–663.
Google Scholar | Crossref | Medline Pantoni, MM, Anagnostaras, SG (2019) Cognitive effects of MDMA in laboratory animals: A systematic review focusing on dose. Pharmacological Reviews 71(3): 413–449.
Google Scholar | Crossref | Medline Patel, R, Titheradge, D (2015) MDMA for the treatment of mood disorder: All talk no substance? Therapeutic Advances in Psychopharmacology 5(3): 179–188.
Google Scholar | SAGE Journals | ISI Saleemi, S, Pennybaker, SJ, Wooldridge, M, et al. (2017) Who is “Molly”? MDMA adulterants by product name and the impact of harm-reduction services at raves. Journal of Psychopharmacology 31(8): 1056–1060.
Google Scholar | SAGE Journals | ISI Sexton, JD, Nichols, CD, Hendricks, PS (2020) Population survey data informing the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics. Frontiers in Psychiatry 10: 896.
Google Scholar | Crossref | Medline Sheehan, DV, Harnett-Sheehan, K, Raj, BA (1996) The measurement of disability. International Clinical Psychopharmacology, Suppl 113: 89–95.
Google Scholar | Crossref Simonsson, O, Sexton, JD, Hendricks, PS (2021) Associations between lifetime classic psychedelic use and markers of physical health. Journal of Psychopharmacology 35: 447–452.
Google Scholar | SAGE Journals | ISI Sordo, L, Chahua, M, Bravo, MJ, et al. (2012) Depression among regular heroin users: The influence of gender. Addictive Behaviors 37(1): 148–152.
Google Scholar | Crossref | Medline ter Bogt, TFM, Engels, RCME, Dubas, JS (2006) Party people: Personality and MDMA use of house party visitors. Addictive Behaviors 31(7): 1240–1244.
Google Scholar | Crossref | Medline Turner, EH, Matthews, AM, Linardatos, E, et al. (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 358(3): 252–260.
Google Scholar | Crossref | Medline | ISI